中国P站

Precision Oncology; Circulating Tumor DNA (ctDNA); Liquid Biopsy; Next-Generation Sequencing (NGS); Tumor Mutational Burden (TMB); Immunoscore; Metabolomics; Exosomes; Artificial Intelligence (AI); Spatial Multi-omics; Single-cell Sequencing; Cancer Biomarkers

Introduction

Precision oncology is rapidly transforming cancer management by leveraging advanced molecular insights and innovative technologies. One significant area of focus is the critical role of circulating tumor DNA (ctDNA) in guiding precision oncology approaches. This includes its diverse clinical applications from early detection and minimal residual disease monitoring to helping select treatments and understand resistance mechanisms. It also offers valuable non-invasive, real-time insights for integrating ctDNA into routine cancer management [1].

Progress in liquid biopsy biomarkers is quite significant for the early detection of various cancers. Novel approaches and technologies, like ctDNA, circulating tumor cells (CTCs), exosomes, and other extracellular vesicles, are promising. They show great potential to transform cancer screening and diagnosis, leading to improved patient outcomes [2].

The emerging field of spatial multi-omics also contributes significantly to precision oncology. These technologies enable detailed analysis of the tumor microenvironment and cellular interactions within their native spatial context. This provides unprecedented insights into tumor heterogeneity, resistance mechanisms, and potential therapeutic targets [3].

Next-Generation Sequencing (NGS) is another cornerstone in cancer precision medicine. It facilitates comprehensive genomic profiling, which helps identify actionable mutations, guides treatment selection, and monitors disease progression. However, challenges related to data interpretation and accessibility still need addressing [4].

Beyond genomic sequencing, tumor mutational burden (TMB) is an important predictive biomarker. It helps predict responses to immune checkpoint inhibitors in various cancer types. Assessing TMB in clinical practice is evolving, with future efforts focused on optimizing its role in patient stratification and immunotherapy decision-making [5].

Immunoscore, a novel prognostic and predictive biomarker, quantifies immune cell infiltrates within the tumor microenvironment. It's a powerful tool for predicting patient outcomes and therapy responses in solid cancers, offering more refined stratification than traditional histopathological staging [6].

Metabolomics is also a rapidly advancing field in oncology, moving from biomarker discovery to clinical applications. Metabolic profiling provides critical insights into cancer diagnosis, prognosis, treatment response, and recurrence. It serves as a valuable complementary approach to genomic and proteomic analyses [7].

Exosomes are gaining interest as promising liquid biopsy biomarkers for cancer. Their role in intercellular communication means their cargo—proteins, lipids, and nucleic acids—can reflect the tumor’s status. This makes them valuable for non-invasive early diagnosis, monitoring disease progression, and predicting therapeutic responses [8].

Artificial Intelligence (AI) is transforming precision oncology, impacting areas from genomics and imaging to clinical decision support. AI algorithms significantly enhance biomarker discovery, personalize treatment strategies, and ultimately improve patient outcomes by integrating complex datasets and providing predictive insights [9].

Finally, single-cell sequencing technologies have seen significant advancements, proving crucial in cancer research. These methods are essential for unraveling tumor heterogeneity, identifying rare cell populations, and pinpointing novel therapeutic targets. This paves the way for more personalized and effective cancer treatments [10].

Description

This article explores the critical role of circulating tumor DNA (ctDNA) in precision oncology, covering its diverse clinical applications from early detection and minimal residual disease monitoring to guiding treatment selection and resistance mechanisms. It highlights both current clinical utility and future directions for integrating ctDNA into routine cancer management, emphasizing its non-invasive nature and real-time insights [1]. The broader field of liquid biopsy leverages advancements in biomarkers like circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and other extracellular vesicles for early cancer detection. These novel approaches hold immense potential to revolutionize screening and diagnosis, ultimately improving patient outcomes [2]. Specifically, exosomes themselves are drawing significant attention as liquid biopsy biomarkers due to their role in intercellular communication. Their cargo, including proteins, lipids, and nucleic acids, offers a non-invasive way to reflect tumor status, assisting in early diagnosis, disease monitoring, and predicting therapeutic responses [8].

Advanced molecular profiling technologies are fundamental to precision oncology. Next-Generation Sequencing (NGS) is central to cancer precision medicine, enabling comprehensive genomic profiling. This allows for the identification of actionable mutations, informs treatment selection, and aids in monitoring disease progression, though challenges exist in data interpretation and accessibility [4]. The emerging field of spatial multi-omics further enhances these capabilities, providing detailed analyses of the tumor microenvironment and cellular interactions in their native spatial context. This provides unprecedented insights into tumor heterogeneity, resistance mechanisms, and potential therapeutic targets [3]. Moreover, significant advancements in single-cell sequencing technologies are crucial for unraveling tumor heterogeneity, identifying rare cell populations, and pinpointing novel therapeutic targets, thereby facilitating more personalized and effective cancer treatments [10].

Biomarkers that predict response to therapy, especially immunotherapy, are vital. Tumor mutational burden (TMB) serves as a predictive biomarker for the efficacy of immune checkpoint inhibitors across various cancer types. The current landscape of TMB assessment in clinical practice is constantly evolving, with ongoing efforts to optimize its role in patient stratification and treatment decision-making for immunotherapy [5]. Another innovative biomarker is Immunoscore, which is both prognostic and predictive. It quantifies immune cell infiltrates within the tumor microenvironment, offering a powerful tool for predicting patient outcomes and treatment response in solid cancers, providing a more refined stratification than traditional staging methods [6].

Complementary approaches like metabolomics are gaining traction in oncology. This rapidly advancing field identifies novel biomarkers and has potential clinical applications, providing insights into cancer diagnosis, prognosis, treatment response, and recurrence. Metabolomics acts as a valuable complement to genomic and proteomic analyses [7]. Integrating these diverse data streams is crucial, and Artificial Intelligence (AI) plays a transformative role in precision oncology. AI spans genomics, imaging, and clinical decision support, using algorithms to enhance biomarker discovery, personalize treatment strategies, and improve patient outcomes by synthesizing complex datasets and offering predictive insights [9].

Conclusion

Precision oncology is advancing rapidly, transforming cancer management through novel biomarkers and technologies. Key among these is circulating tumor DNA (ctDNA), offering non-invasive, real-time insights for early detection, minimal residual disease monitoring, and guiding treatment selection, as well as understanding resistance mechanisms. This emphasis on ctDNA extends to broader liquid biopsy approaches, which encompass other biomarkers like circulating tumor cells (CTCs) and exosomes, all holding significant potential for improved screening and diagnosis across various cancers. Complementing these biomarker discoveries are advancements in high-throughput technologies. Next-Generation Sequencing (NGS) enables comprehensive genomic profiling for identifying actionable mutations and monitoring disease progression. The emerging field of spatial multi-omics provides detailed analysis of the tumor microenvironment and cellular interactions in their native context, offering unprecedented insights into heterogeneity and therapeutic targets. Similarly, single-cell sequencing technologies unravel tumor heterogeneity and pinpoint rare cell populations for personalized treatments. Beyond genomic and cellular insights, other biomarkers like tumor mutational burden (TMB) predict responses to immune checkpoint inhibitors. Immunoscore quantifies immune cell infiltrates for prognostic and predictive value in solid cancers. Metabolomics, another complementary approach, explores metabolic profiling for diagnosis, prognosis, and treatment response. Artificial Intelligence (AI) plays a pivotal role, integrating complex datasets from genomics and imaging to enhance biomarker discovery, personalize treatment strategies, and improve patient outcomes through predictive insights. Together, these innovations are paving the way for more personalized and effective cancer therapies, redefining the landscape of oncology.

References

1. Chetan B, Isaac K, Nickolas P (2024) .Nat Rev Clin Oncol 21:227-241.

   , ,

2. Jian Z, Hong L, Tie L (2023) .Signal Transduct Target Ther 8:333.

   , ,

3. Kui J, Feng L, Yanan Y (2023) .Mol Cancer 22:101.

   , ,

4. Xuemei L, Shunlin C, Jianping W (2022) .Cancer Lett 547:215777.

   , ,

5. Ashley MG, Shumei K, Sandip PP (2022) .Mol Cancer Ther 21:695-709.

   , ,

6. Bernhard M, Guy B, Florence P (2021) .Semin Cancer Biol 73:234-241.

   , ,

7. Yanfang W, Xiaoli Z, Shujie L (2021) .Cancers (Basel) 13:5948.

   , ,

8. Xiaoxia L, Yu W, Jian X (2020) .Curr Med Chem 27:6197-6218.

   , ,

9. Hamad A, Ahmed A, Abdulatif A (2023) .Cancers (Basel) 15:3715.

   , ,

10. Guojun C, Zhengsheng H, Yonggui L (2022) .J Hematol Oncol 15:75.

    , ,